Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Generics Maker Watson To Buy Rival Actavis

by Michael McCoy
April 30, 2012 | A version of this story appeared in Volume 90, Issue 18

The generic drug maker Watson Pharmaceuticals has agreed to acquire its rival Actavis for about $5.6 billion. Watson says the purchase will create the world’s third-largest generics company after Teva Pharmaceutical Industries and Sandoz. Watson’s generics sales last year were $3.4 billion; Actavis’ were $2.3 billion. The overall sales of the two firms this year are expected to reach $8.0 billion. Watson CEO Paul M. Bisaro says the purchase of the Icelandic firm will substantially boost Watson’s international presence. He also anticipates savings of more than $300 million from the combination.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.